Menu
Search
|

Menu

Close
X

TapImmune Inc TPIV.OQ (NASDAQ Stock Exchange Capital Market)

10.13 USD
-- (--)
As of 1:30 AM IST
chart
Previous Close 10.13
Open --
Volume --
3m Avg Volume 83,737
Today’s High --
Today’s Low --
52 Week High 13.54
52 Week Low 2.60
Shares Outstanding (mil) 10.16
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.301
FY17
-0.644
FY16
-0.367
FY15
-17.933
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
--
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.72
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
-911.19
14.61
Return on Equity (TTM)
vs sector
-911.19
16.34

EXECUTIVE LEADERSHIP

Peter Hoang
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Michael Loiacono
Chief Financial Officer, Chief Accounting Officer, Treasurer, Corporate Secretary, Since 2016
Salary: --
Bonus: --
Mark Reddish
Vice President Development, Since 2014
Salary: $15,000.00
Bonus: --
Richard Kenney
Acting Chief Medical Officer, Since 2017
Salary: --
Bonus: --
David Laskow-Pooley
Director, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

5 W Forsyth St Ste 200
JACKSONVILLE   FL   32202-3676

Phone: +1904.5165436

TapImmune Inc. is an immuno-oncology company. The Company specializes in the development of peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer. The Company is engaged in developing vaccines that target candidate breast cancers, colorectal cancers, ovarian cancers and non-small cell lung cancers. The Company combines a set of licensed technologies, including peptide antigen technologies and deoxyribonucleic acid (DNA) expression technologies that improve the ability of the cellular immune system to recognize and destroy diseased cells. The Company's core technology platforms include TPIV 100/110, a vaccine for the treatment of Human Epidermal Growth Factor receptor 2 (HER2)/neu+ breast cancer that over-expresses HER2/neu; TPIV 200, a vaccine for treating breast and ovarian cancers that over-express Folate Receptor Alpha, and DNA expression vaccine technology (Polystart) for further treating various cancers or infectious disease.

SPONSORED STORIES